Skip to content
2000
image of Infection Screening and Vaccination of Adult and Pediatric Patients with Autoimmune Inflammatory Rheumatic Diseases: An Emirati Delphi 
Consensus

Abstract

Introduction

Patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have an increased susceptibility to infections due to their compromised immune systems and the use of immunosuppressive therapies. Infections are a leading cause of morbidity and mortality in these patients, emphasizing the need for strategies such as infection control and vaccination to prevent avoidable harm to both patients and healthcare workers. This study aims to provide expert consensus on infection screening and vaccination guidelines for AIIRD patients.

Methods

A task force of experts from the United Arab Emirates developed a set of statements based on available evidence and expert opinion. The consensus was structured into two main categories: infection screening (9 statements with 23 sub-statements) and vaccination (7 statements).

Results

The infection screening consensus covered nine key areas: tuberculosis (TB) screening (I.1), methods and periodicity of TB screening (I.2), strategies for managing positive IGRA test results (I.3), and infection control for hepatitis B (I.4), hepatitis C (I.5), HIV (I.6), varicella-zoster virus (I.7), and Pneumocystis jirovecii (I.8). The vaccination consensus included recommendations on general vaccination principles (V.0) and specific vaccinations for influenza (V.1), pneumococcal disease (V.2), human papillomavirus (HPV) (V.3), varicella-zoster virus (V.4), tetanus (V.5), and COVID-19 (V.6). Delphi voting showed strong consensus among the task force experts, validating their relevance and applicability for clinicians managing AIIRD patients.

Conclusion

This Emirati consensus provides up-to-date guidance and recommendations for clinicians to enhance the care and safety of AIIRD patients.

Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971368196250117105119
2025-01-21
2025-07-11
Loading full text...

Full text loading...

References

  1. van der Heijde D. Daikh D.I. Betteridge N. Burmester G.R. Hassett A.L. Matteson E.L. van Vollenhoven R. Lakhanpal S. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann. Rheum. Dis. 2018 77 6 829 832 10.1136/annrheumdis‑2017‑212565 29525777
    [Google Scholar]
  2. American College of Rheumatology (ACR) Rheumatic diseases in America: The problem, the impact, and the answers. 2012 Available from: https://www.bu.edu/enact/files/2012/10/ACR_Whitepaper_SinglePg.pdf Accessed November 11, 2023.
  3. Falagas M.E. Manta K.G. Betsi G.I. Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: A systematic review. Clin. Rheumatol. 2007 26 5 663 670 10.1007/s10067‑006‑0441‑9 17186117
    [Google Scholar]
  4. Furer V. Rondaan C. Heijstek M. van Assen S. Bijl M. Agmon-Levin N. Breedveld F.C. D’Amelio R. Dougados M. Kapetanovic M.C. van Laar J.M. Ladefoged de Thurah A. Landewé R. Molto A. Müller-Ladner U. Schreiber K. Smolar L. Walker J. Warnatz K. Wulffraat N.M. Elkayam O. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): A systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 2019 5 2 e001041 10.1136/rmdopen‑2019‑001041 31673420
    [Google Scholar]
  5. Fragoulis G.E. Dey M. Zhao S. Schoones J. Courvoisier D. Galloway J. Hyrich K.L. Nikiphorou E. Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open 2022 8 2 e002726 10.1136/rmdopen‑2022‑002726 36323488
    [Google Scholar]
  6. Fragoulis G.E. Nikiphorou E. Dey M. Zhao S.S. Courvoisier D.S. Arnaud L. Atzeni F. Behrens G.M. Bijlsma J.W. Bohm P. Constantinou C.A. Garcia-Diaz S. Kapetanovic M.C. Lauper K. Luis M. Morel J. Nagy G. Poleverino E. van Rompay J. Sebastiani M. Strangfeld A. de Thurah A. Galloway J. Hyrich K.L. EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 2022 2022 10.1136/ard‑2022‑223335 36328476
    [Google Scholar]
  7. Bass A.R. Chakravarty E. Akl E.A. Bingham C.O. Calabrese L. Cappelli L.C. Johnson S.R. Imundo L.F. Winthrop K.L. Arasaratnam R.J. Baden L.R. Berard R. Bridges S.L. Jr Cheah J.T.L. Curtis J.R. Ferguson P.J. Hakkarinen I. Onel K.B. Schultz G. Sivaraman V. Smith B.J. Sparks J.A. Vogel T.P. Williams E.A. Calabrese C. Cunha J.S. Fontanarosa J. Gillispie-Taylor M.C. Gkrouzman E. Iyer P. Lakin K.S. Legge A. Lo M.S. Lockwood M.M. Sadun R.E. Singh N. Sullivan N. Tam H. Turgunbaev M. Turner A.S. Reston J. 2022 american college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023 75 3 333 348 10.1002/art.42386 36597810
    [Google Scholar]
  8. Galal B. Lazieh S. Al-Ali S. Khoshnood K. Assessing vaccine hesitancy in Arab countries in the Middle East and North Africa (MENA) region: A scoping review protocol. BMJ Open 2022 12 2 e045348 10.1136/bmjopen‑2020‑045348 35149559
    [Google Scholar]
  9. Kaadan M.I. Abdulkarim J. Chaar M. Zayegh O. Keblawi M.A. Determinants of COVID-19 vaccine acceptance in the Arab world: A cross-sectional study. Glob. Health Res. Policy 2021 6 1 23 10.1186/s41256‑021‑00202‑6 34253254
    [Google Scholar]
  10. Suliman D.M. Nawaz F.A. Mohanan P. Modber M.A.K.A. Musa M.K. Musa M.B. El Chbib D. Elhadi Y.A.M. Essar M.Y. Isa M.A. Lucero-Prisno D.E. III Moonesar I.A. UAE efforts in promoting COVID-19 vaccination and building vaccine confidence. Vaccine 2021 39 43 6341 6345 10.1016/j.vaccine.2021.09.015 34561138
    [Google Scholar]
  11. Barrett D. Heale R. What are Delphi studies? Evid. Based Nurs. 2020 23 3 68 69 10.1136/ebnurs‑2020‑103303 32430290
    [Google Scholar]
  12. Nasa P. Jain R. Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. World J. Methodol. 2021 11 4 116 129 10.5662/wjm.v11.i4.116 34322364
    [Google Scholar]
  13. Centers for Disease Control and Prevention (CDC) Vaccine Recommendations and Guidelines of the ACIP: Varicella ACIP Vaccine Recommendations. 2014 Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html Accessed November 29, 2023.
  14. Centers for Disease Control and Prevention (CDC) Clinical Considerations for Use of Recombinant Zoster Vaccine (RZV, Shingrix) in Immunocompromised Adults Aged ≥19 Years. 2022 Available from: https://www.cdc.gov/shingles/vaccination/immunocompromised-adults.html Accessed April 19, 2023.
  15. Centers for Disease Control and Prevention (CDC) Pneumococcal Vaccine Timing for Adults. 2023 Available from: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf Accessed March 9, 2023.
  16. Ng J. Delphi method: A qualitative approach for quantitative results. Value Health 2018 21 Supplement 1 S54 10.1016/j.jval.2018.04.447
    [Google Scholar]
  17. Neves R. De Dios Perez B. Panek R. Jagani S. Wilne S. Bhatt J.M. Caputi C. Cirillo E. Coman D.J. Dückers G. Gilbert D.L. Kay Koenig M. Mansour L. McDermott E. Pauni M. Pignata C. Perlman S.L. Porras O. Betina Porto M. Schon K. Soler-Palacin P. Nick Russo S. Takagi M. Tischkowitz M. Wainwright C. Dandapani M. Glazebrook C. Suri M. Whitehouse W.P. Dineen R.A. Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi‐based consensus survey of international experts. Cancer Med. 2023 12 13 14663 14673 10.1002/cam4.6075 37264737
    [Google Scholar]
  18. Youssef J. Novosad S.A. Winthrop K.L. Infection risk and safety of corticosteroid use. Rheum. Dis. Clin. North Am. 2016 42 1 157 176, ix-x 10.1016/j.rdc.2015.08.004 26611557
    [Google Scholar]
  19. The World Health Organization (WHO) Tuberculosis profile: United Arab Emirates. 2023 Available from: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&iso2=%22AE%22&lan=%22EN%22 Accessed November 28, 2023.
  20. Statista Incidence rate of tuberculosis in the United Arab Emirates from 2005 to 2021. 2023 Available from: https://www.statista.com/statistics/681416/uae-incidents-of-tbc-per-100-000-inhabitants/ Accessed November 28, 2023.
  21. Al Hosani F.I. Yahia G.A. Prevalence of pulmonary tuberculosis among expatriates subjected to medical visa screening in Abu Dhabi, United Arab Emirates. J. Epidemiol. Glob. Health 2013 3 1 23 30 10.1016/j.jegh.2012.12.003 23856535
    [Google Scholar]
  22. Kang J. Jeong D.H. Yoo B. Lee C.K. Kim Y.G. Hong S. Shim T.S. Jo K.W. The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. Respir. Med. 2018 143 109 115 10.1016/j.rmed.2018.09.005 30261981
    [Google Scholar]
  23. Tan J. Zhou J. Zhao P. Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin. Rheumatol. 2012 31 8 1169 1175 10.1007/s10067‑012‑1988‑2 22544263
    [Google Scholar]
  24. Laohapand C. Arromdee E. Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol. Int. 2015 9 2 202 208 10.1007/s12072‑014‑9597‑6 25788188
    [Google Scholar]
  25. Costa L. Caso F. Atteno M. Giannitti C. Spadaro A. Ramonda R. Vezzù M. Del Puente A. Morisco F. Fiocco U. Galeazzi M. Punzi L. Scarpa R. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients. Clin. Rheumatol. 2014 33 2 273 276 10.1007/s10067‑013‑2378‑0 23975363
    [Google Scholar]
  26. Goverment of Dubai Dubai Health Authority Launches "Early Detection of Hepatitis C" Campaign. 2023 Available from: https://www.dha.gov.ae/en/media/news/831?ref=home Accessed November 28, 2023.
  27. Dubai Health Authorities (DHA) & Dubai Health Insurance Corporation (DHIC) Hepatitis C Patient Support Program. 2022 Available from: https://www.isahd.ae/content/docs/PD%20PSP%20Program_Hepatitis%20C%20Guidelines_24-11-2020.pdf Accessed November 28, 2023.
  28. Petri M. Allbritton J. Antibiotic allergy in systemic lupus erythematosus: A case-control study. J. Rheumatol. 1992 19 2 265 269 1629825
    [Google Scholar]
  29. Suyama Y. Okada M. Rokutanda R. Min C. Sassé B. Kobayashi D. Takahashi O. Deshpande G.A. Matsui K. Kawaguchi Y. Kishimoto M. Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study. Mod. Rheumatol. 2016 26 4 557 561 10.3109/14397595.2015.1112467 26587755
    [Google Scholar]
  30. Zawodniak A. Lochmatter P. Beeler A. Pichler W.J. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int. Arch. Allergy Immunol. 2010 153 2 152 156 10.1159/000312632 20413982
    [Google Scholar]
  31. Furer V. Rondaan C. Heijstek M.W. Agmon-Levin N. van Assen S. Bijl M. Breedveld F.C. D’Amelio R. Dougados M. Kapetanovic M.C. van Laar J.M. de Thurah A. Landewé R.B.M. Molto A. Müller-Ladner U. Schreiber K. Smolar L. Walker J. Warnatz K. Wulffraat N.M. Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 2020 79 1 39 52 10.1136/annrheumdis‑2019‑215882 31413005
    [Google Scholar]
  32. Curtis J.R. Johnson S.R. Anthony D.D. Arasaratnam R.J. Baden L.R. Bass A.R. Calabrese C. Gravallese E.M. Harpaz R. Kroger A. Sadun R.E. Turner A.S. Williams E.A. Mikuls T.R. American college of rheumatology guidance for COVID ‐19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 4. Arthritis Rheumatol. 2022 74 5 e21 e36 10.1002/art.42109 35474640
    [Google Scholar]
  33. Park J.K. Lee Y.J. Shin K. Kang E.H. Ha Y.J. Park J.W. Kim M.J. Kim M.H. Choi S.R. Jung Y. Lee J.H. In Jung J. Kim J.Y. Winthrop K.L. Lee E.B. A multicenter, prospective, randomized, Parallel‐Group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis. Arthritis Rheumatol. 2023 75 2 171 177 10.1002/art.42318 35930728
    [Google Scholar]
  34. Grohskopf L.A. Blanton L.H. Ferdinands J.M. Chung J.R. Broder K.R. Talbot H.K. Morgan R.L. Fry A.M. Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices — United States, 2022–23 influenza season. MMWR Recomm. Rep. 2022 71 1 1 28 10.15585/mmwr.rr7101a1 36006864
    [Google Scholar]
  35. Rákóczi É. Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open 2017 3 2 e000484 10.1136/rmdopen‑2017‑000484 28955497
    [Google Scholar]
  36. Winthrop K. Bingham C. Immunizations in autoimmune inflammatory rheumatic disease in adults. 2023 Available from: https://www.uptodate.com/contents/immunizations-in-autoimmune-inflammatory-rheumatic-disease-in-adults/print Accessed November 28, 2023.
  37. Al Shdefat S. Al Awar S. Osman N. Khair H. Sallam G. Elbiss H. Health care system view of Human Papilloma Virus (HPV) vaccine acceptability by emirati men. Comput. Math. Methods Med. 2022 2022 1 11 10.1155/2022/8294058 35126638
    [Google Scholar]
  38. Bruni L. Albero G. Serrano B. Mena M. Collado J. Gómez D. Muñoz J. Bosch F. de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) Human Papillomavirus and Related Diseases in United Arab Emirates. 2023 Available from: https://hpvcentre.net/statistics/reports/ARE.pdf Accessed November 28, 2023.
  39. Bühler S. Jaeger V.K. Adler S. Bannert B. Brümmerhoff C. Ciurea A. Distler O. Franz J. Gabay C. Hagenbuch N. Herzog C. Hasler P. Kling K. Kyburz D. Müller R. Nissen M.J. Siegrist C.A. Villiger P.M. Walker U.A. Hatz C. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study. Rheumatology (Oxford) 2019 58 9 1585 1596 10.1093/rheumatology/kez045 30877773
    [Google Scholar]
  40. Borchers A.T. Chang C. Gershwin M.E. Gershwin L.J. Respiratory syncytial virus--a comprehensive review. Clin. Rev. Allergy Immunol. 2013 45 3 331 379 10.1007/s12016‑013‑8368‑9 23575961
    [Google Scholar]
  41. Obando-Pacheco P. Justicia-Grande A.J. Rivero-Calle I. Rodríguez-Tenreiro C. Sly P. Ramilo O. Mejías A. Baraldi E. Papadopoulos N.G. Nair H. Nunes M.C. Kragten-Tabatabaie L. Heikkinen T. Greenough A. Stein R.T. Manzoni P. Bont L. Martinón-Torres F. Respiratory syncytial virus seasonality: A global overview. J. Infect. Dis. 2018 217 9 1356 1364 10.1093/infdis/jiy056 29390105
    [Google Scholar]
  42. Belongia E.A. King J.P. Kieke B.A. Pluta J. Al-Hilli A. Meece J.K. Shinde V. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect. Dis. 2018 5 12 ofy316 10.1093/ofid/ofy316 30619907
    [Google Scholar]
  43. Falsey A.R. McElhaney J.E. Beran J. van Essen G.A. Duval X. Esen M. Galtier F. Gervais P. Hwang S.J. Kremsner P. Launay O. Leroux-Roels G. McNeil S.A. Nowakowski A. Richardus J.H. Ruiz-Palacios G. St Rose S. Devaster J.M. Oostvogels L. Durviaux S. Taylor S. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J. Infect. Dis. 2014 209 12 1873 1881 10.1093/infdis/jit839 24482398
    [Google Scholar]
  44. Lee N. Lui G.C.Y. Wong K.T. Li T.C.M. Tse E.C.M. Chan J.Y.C. Yu J. Wong S.S.M. Choi K.W. Wong R.Y.K. Ngai K.L.K. Hui D.S.C. Chan P.K.S. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 2013 57 8 1069 1077 10.1093/cid/cit471 23876395
    [Google Scholar]
  45. Shi T. Denouel A. Tietjen A.K. Campbell I. Moran E. Li X. Campbell H. Demont C. Nyawanda B.O. Chu H.Y. Stoszek S.K. Krishnan A. Openshaw P. Falsey A.R. Nair H. Nair H. Campbell H. Shi T. Zhang S. Li Y. Openshaw P. Wedzicha J. Falsey A. Miller M. Beutels P. Bont L. Pollard A. Molero E. Martinon-Torres F. Heikkinen T. Meijer A. Fischer T.K. van den Berge M. Giaquinto C. Mikolajczyk R. Hackett J. Cai B. Knirsch C. Leach A. Stoszek S.K. Gallichan S. Kieffer A. Demont C. Denouel A. Cheret A. Gavart S. Aerssens J. Fuentes R. Rosen B. Nair H. Campbell H. Shi T. Zhang S. Li Y. Openshaw P. Wedzicha J. Falsey A. Miller M. Beutels P. Bont L. Pollard A. Molero E. Martinon-Torres F. Heikkinen T. Meijer A. Fischer T.K. van den Berge M. Giaquinto C. Mikolajczyk R. Hackett J. Cai B. Knirsch C. Leach A. Stoszek S.K. Gallichan S. Kieffer A. Demont C. Denouel A. Cheret A. Gavart S. Aerssens J. Fuentes R. Rosen B. RESCEU Investigators Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis. J. Infect. Dis. 2020 222 Suppl. 7 S577 S583 10.1093/infdis/jiz059 30880339
    [Google Scholar]
  46. Papi A. Ison M.G. Langley J.M. Lee D.G. Leroux-Roels I. Martinon-Torres F. Schwarz T.F. van Zyl-Smit R.N. Campora L. Dezutter N. de Schrevel N. Fissette L. David M.P. Van der Wielen M. Kostanyan L. Hulstrom V. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023 388 7 595 608 10.1056/NEJMoa2209604 36791160
    [Google Scholar]
/content/journals/crr/10.2174/0115733971368196250117105119
Loading
/content/journals/crr/10.2174/0115733971368196250117105119
Loading

Data & Media loading...

Supplements

Supplementary Table 1: Available medications for AIIRD in the UAE. Supplementary Table 2: Treatment options for patients with latent tuberculosis Supplementary Table 3: PCP Prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) in patients with AIIRD (level of evidence) Supplementary Table 4: Available vaccines in the UAE. Supplementary Table 5: Immunosuppressive medication management at the time of live attenuated virus vaccine administration Supplementary Table 6: Guidance Related to the Use and Timing of Vaccine Dosing and Immunomodulatory Therapy in Relation to COVID-19 Vaccination in patients with AIIRD. Supplementary Table 7: Dosage of EVUSHELD for prophylaxis. Supplementary material is available on the publisher’s website along with the published article.


  • Article Type:
    Research Article
Keywords: expert ; vaccination ; Delphi consensus ; rheumatic diseases ; infection control
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test